Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant
and escalating global challenges. Its etiology is intricate and diverse, stemming from a …

Abstract Alzheimer's disease (AD), as the fourth leading cause of death among the elderly
worldwide, has brought enormous challenge to the society. Due to its extremely complex …

In June 2021, the world was informed about a new drug for Alzheimer's disease approved
by the FDA. Aducanumab (BIIB037, ADU), being a monoclonal antibody IgG1, is the newest …

Aducanumab is a novel disease‐modifying anti‐amyloid‐beta (Aβ) human monoclonal
antibody specifically targeted to the pathophysiology of Alzheimer's disease (AD). It was …

The amyloid cascade is the most frequently accepted hypothesis of Alzheimer's Disease
(AD). According to this hypothesis, the formation of plaques precedes the appearance of …

Since glucose reuptake by neurons is mostly independent of insulin, it has been an
intriguing question whether insulin has or not any roles in the brain. Consequently, the …

Alzheimer's disease (AD) is the world's leading cause of dementia and has become a huge
economic burden on nations and families. However, the exact etiology of AD is still …

Due to the hugely important roles of neurotransmitter acetylcholine (ACh) and amyloid-β
(Aβ) in the pathogenesis of Alzheimer's disease (AD), the development of multi-target …

Background: Alzheimer's disease (AD) is a serious neurodegenerative disease associated
with the memory and cognitive impairment. The occurrence of AD is due to the accumulation …

One of the primary obstacles in treating central nervous system (CNS) disorders lies in the
limited ability of disease-modifying drugs to cross the blood-brain barrier (BBB). Our …